Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits

Abstract

A method for preventing clotting in an extracorporeal blood circuit by administering a synthetic oligosaccharide that is a selective inhibitor of factor Xa, acting via antithrobmin III.

1 . A method for preventing clotting in an extracorporeal blood circuit, induced by contact with surfaces, for a patient undergoing chronic, intermittent, extracorporeal blood treatment, comprising:  
       administering to the patient for each treatment an amount of from 0.001 to 10 mg of methyl O-(3,4-di-O-methyl-2,6-di-O-sulpho-α-D-glucopyranosyl-(1→4)-O-(3-O-methyl-2-O-sulpho-β-D-glucopyranosyl uronic acid)-(1→4)-O-(2,36-tri-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(3-O-methyl-2-O-sulpho-α-L-idopyranosyl uronic acid)-(1→4)-(2,3,6-tri-O-sulpho-α-D-glucopyranoside, or a salt thereof, per kg body weight of the patient.  
     
     
         2 . A method for preventing clotting in an extracorporeal blood circuit, induced by contact with surfaces, for a patient undergoing chronic, intermittent, extracorporeal blood treatment, comprising:  
       administering to the patient for each treatment an amount of from 0.30 to 30 mg of methyl O-(3,4-di-O-methyl-2,6-di-O-sulpho-α-D-glucopyranosyl-(1→4)-O-(3-O-methyl-2-O-sulpho-β-D-glucopyranosyl uronic acid)-(1→4)-O--2,3,6-tri-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(3-O-methyl-2-O-sulpho-α-L-idopyranosyl uronic acid)-(1→4)-2,3,6-tri-O-sulpho-α-D-glucopyranoside, or salt thereof.  
     
     
         3 . The method of  claim 1 , comprising administering a dodecasodium salt thereof.  
     
     
         4 . The method of  claim 2 , comprising administering a dodecasodium salt thereof.  
     
     
         5 . A method for preventing clotting in an extracorporeal blood circuit, induced by contact with surfaces, for a patient undergoing chronic, intermittent, extracorporeal blood treatment, comprising:  
       administering to the patient for each treatment an amount of from 0.001 to 10 mg of methyl O-(2,3,4-tri-O-methyl-6-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(2,3-di-O-methyl-β-D-glucopyranosyl uronic acid)-(1→4)-O-(2,3,6-tri-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(2,3-di-O-methyl-α-L-idopyranosyl uronic acid)-(1→4)-2,3,6,-tri-O-sulpho-α-D-glucopyranoside, or a salt thereof, per kg body weight of the patient.  
     
     
         6 . A method for preventing clotting in an extracorporeal blood circuit, induced by contact with surfaces, for a patient undergoing chronic, intermittent, extracorporeal blood treatment, comprising:  
       administering to the patient for each treatment an amount of from 0.30 to 30 mg of methyl O-(2,3,4-tri-O-methyl-6-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(2,3-di-O-methyl-β-D-glucopyranosyl uronic acid)-(1→4)-O-(2,3,6-tri-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(2,3-di-O-methyl-α-L-idopyranosyl uronic acid)-(1→4)-2,3,6,-tri-O-sulpho-α-D-glucopyranoside, or a salt thereof.  
     
     
         7 . The method of  claim 5 , comprising administering a nonasodium salt thereof.  
     
     
         8 . The method of  claim 6 , comprising administering a nonasodium salt thereof.  
     
     
         9 . A method for preventing clotting in an extracorporeal blood circuit, induced by contact with surfaces, for a patient undergoing chronic, intermittent, extracorporeal blood treatment, comprising:  
       administering to the circuit for each treatment an amount form 0.001 to 10 mg of methyl O-(3,4-di-O-methyl-2,6-di-O-sulpho-α-D-glucopyranosyl-(1→4)-O-(3-O-methyl-2-O-sulpho-β-D-glucopyranosyl uronic acid)-(1→4)-O-(2,3,6-tri-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(3-O-methyl-2-O-sulpho-α-L-idipyranosyl uronic acid)-(1→4)-2,3,6-tri-O-sulpho-α-D-glucopyranoside, or salt thereof, per kg body weight of the patient.  
     
     
         10 . A method for preventing clotting in an extracorporeal blood circuit, induced by contact with surfaces, for a patient undergoing chronic, intermittent, extracorporeal blood treatment, comprising:  
       administering to the circuit for each treatment an amount of from 0.30 to 30 mg of methyl O-(3,4-di-O-methyl-2,6-di-O-sulpho-α-D-glucopyranosyl-(1→4)-O-(3-O-methyl-2-O-sulpho-β-D-glucopyranosyl uronic acid)-(1→4)-O-(2,3,6-tri-O-sulpho-α-D-glucopyranosyl)-(→4)-O-(3-O-methyl-2-O-sulpho-α-L-idopyranosyl uronic acid)-(1→4)-(2,3,6-tri-O-sulpho-α-D-glucopyranoside or a salt thereof.  
     
     
         11 . The method of  claim 9 , comprising administering a dodecasodium salt thereof.  
     
     
         12 . The method of  claim 10 , comprising administering a dodecasodium salt thereof.  
     
     
         13 . A method for preventing clotting in an extracorporeal blood circuit, induced by contact with surfaces, for a patient undergoing chronic, intermittent, extracorporeal blood treatment, comprising:  
       administering to the circuit for each treatment an amount of from 0.001 to 10 mg of methyl O-(2,3,4-tri-O-methyl-6-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(2,3-di-O-methyl-β-D-glucopyranosyl uronic acid)-(1→4)-O-(2,3,6-tri-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(2,3-di-O-methyl-α-L-idopyranosyl uronic acid)-(1→4)-2,3,6-tri-O-sulpho-α-D-glucopyranoside or a salt thereof per kg body weight of the patient.  
     
     
         14 . A method for preventing clotting induced by contact with surfaces in an extracorporeal blood circuit for a patient undergoing chronic, intermittent, extracorporeal blood treatment comprising:  
       administering to the circuit for each treatment an amount of from 0.30 to 30 mg of methyl O-(2,3,4-tri-O-methyl-6-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(2,3-di-O-methyl-β-D-glucopyranosyl uronic acid)-(1→4)-O-(2,3,6-tri-O-sulpho-α-D-glucopyranosyl)-(1→4)-O-(2,3-di-O-methyl-α-L-idopyranosyl uronic acid)-(1→4)-2,3,6,-tri-O-sulpho-α-D-glucopyranoside or a salt thereof.  
     
     
         15 . The method of  claim 13 , comprising administering a nonasodium salt thereof.  
     
     
         16 . The method of  claim 14 , comprising administering a nonasodium salt thereof.